NCT02411955View on ClinicalTrials.gov

A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris

PHASE1CompletedINTERVENTIONAL

Enrollment

1,077

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

February 28, 2015

Conditions

Acne Vulgaris

Interventions

DRUG

Tazarotene Cream 0.1%

Tazarotene Cream 0.1% applied to lightly cover the entire face once daily for 84 consecutive days.

DRUG

Tazorac®

Tazorac® applied to lightly cover the entire face once daily for 84 consecutive days.

DRUG

Placebo

Placebo (vehicle of the test product) applied to lightly cover the entire face once daily for 84 consecutive days.

All Listed Sponsors

lead

Sun Pharmaceutical Industries, Inc.

INDUSTRY

NCT02411955 - A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris | Biotech Hunter | Biotech Hunter